Nitrome

 Virpax Pharmaceuticals Announces Leadership Transition

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, CNS, Neurogenic inflammation, Silence Therapeutics, Meharry Medical College, Pharmaceutical marketing, Regulatory affairs, Therapy, Post-traumatic stress disorder, Quality assurance, Lincoln University, Commercial Operating System, Pain management, Patient, INSEAD, Merck, Medication, Clobazam, Nitrome, Sanofi, Trustee, Novartis, University, Harvard Medical School, Axovant Sciences, Tennessee State University, Champaign–Urbana metropolitan area, Central nervous system, Business, DSM-IV codes, International business, Pharmaceutical industry, Management, Analgesic, Schizophrenia, Biology, Neurophysiology, Lundbeck, Neuroscience, Droxidopa

Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.

Key Points: 
  • Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
  • He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
  • Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
  • I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.

Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals

Retrieved on: 
Monday, October 2, 2023
Other Health, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Science, Surgery, Biotechnology, Other Science, Health, Lincoln University, Central nervous system, Nitrome, Business, CNS, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Post-traumatic stress disorder, OTC, Pain management, Knowledge, BA, Pharmaceutical industry, Analgesic

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that Gerald W. Bruce has been appointed as President and CEO of Novvae™ Pharmaceuticals , Virpax’s wholly-owned subsidiary focused solely on advancing the Company’s OTC pipeline.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that Gerald W. Bruce has been appointed as President and CEO of Novvae™ Pharmaceuticals , Virpax’s wholly-owned subsidiary focused solely on advancing the Company’s OTC pipeline.
  • Mr. Bruce has spent over 30 years in the pharmaceutical and medical nutrition industries.
  • Most recently, he served as a Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
  • “Gerald, with his background in the pharma and medical nutrition industries, is uniquely positioned to lead Novvae.

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

Retrieved on: 
Monday, August 14, 2023
Industrial engineering, Dyslipidemia, Marketing, Texas A&M University, Cardiovascular disease, Business, NAMS, Apolipoprotein, Bristol Myers Squibb, CCO, AstraZeneca, Boehringer Ingelheim, Migraine, Patient, CETP, M.B.A, Stanford Graduate School of Business, Pfizer, Takeda Pharmaceutical Company, Common, Pharmaceutical industry, Nitrome

Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for industry-leading brands.

Key Points: 
  • Mr. Jones brings 30 years of commercial and launch experience in the U.S. and globally, with particular experience in driving mass market product launch strategies for industry-leading brands.
  • At NewAmsterdam, he will build and lead all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations.
  • Most recently, he served as CCO, Migraine & Common Diseases at Biohaven Pharmaceuticals, which was acquired by Pfizer for $11.6B.
  • During his tenure, Mr. Jones led the commercial enterprise that launched Biohaven’s Nurtec® ODT.

Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management

Retrieved on: 
Thursday, June 22, 2023
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Jennifer Fox, Bear Stearns, Migraine, Depression, Biochemistry, Diabetes, Doctor of Philosophy, Marketing, Schizophrenia, Elizabeth Glaser Pediatric AIDS Foundation, Texas A&M University, Biogen, CMC, Atrial fibrillation, ODT, Business, Atopic dermatitis, MBA, MIT, Merck & Co., Bristol Myers Squibb, Deutsche Bank, AstraZeneca, Prudential Securities, Chronic obstructive pulmonary disease, Chemistry, Organization, Neuroscience, Bank of America, CDMO, Bowdoin College, Citigroup, Engineering, Boehringer Ingelheim, CFO, Merck, United States Department of the Air Force, Bank, Stanford Graduate School of Business, Therapy, Nitrome, Bipolar, Pfizer, Takeda Pharmaceutical Company, Pharmaceutical industry, Management, Manhattan College, Apsis

Additionally, Apogee announced the appointment of Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), as chief technology officer.

Key Points: 
  • Additionally, Apogee announced the appointment of Rebecca Dabora, Ph.D., an expert in chemistry, manufacturing and controls (CMC), as chief technology officer.
  • “We are thrilled to further strengthen the Apogee team with the appointments of both Jennifer and BJ to our board of directors and Becky to our senior management team, and to leverage their respective expertise in the industry,” said Michael Henderson, M.D., chief executive officer of Apogee.
  • Ms. Fox currently serves on the board of directors and as chair of the audit committee of ProKidney Corp. and on the board of directors of Life Science Cares.
  • Dr. Dabora has served in executive roles leading the technical operations function for several companies, including Invivyd, Aspyrian Therapeutics, SwanBio Therapeutics and others.

Eiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of Directors

Retrieved on: 
Monday, July 18, 2022
Human resources, University, Patient, Cigna, PALO, Nasdaq, Boston, Monsanto, Industrial relations, Forbes, Board of directors, Board, Progeria, Vertex Pharmaceuticals, MA, COVID-19, Growth, Boston Business Journal, HDV, Eiger, Strategic planning, Doctor of Philosophy, Champaign County, Illinois, Congenital hyperinsulinism, FDA, Health, Pharmaceutical industry, Management, Fine chemical, AbbVie, Vertex, Nitrome

Ms. Kelly-Croswell is an accomplished senior human resources and organizational executive and brings nearly 25 years of experience in the biopharmaceutical and life sciences industries.

Key Points: 
  • Ms. Kelly-Croswell is an accomplished senior human resources and organizational executive and brings nearly 25 years of experience in the biopharmaceutical and life sciences industries.
  • "Lisa's extensive experience in biopharmaceuticals and healthcare systems alongside her track record in leading meaningful organizational growth ideally position her to bring an important perspective to our board," said Thomas Dietz, PhD, Chairman of the Board, Eiger.
  • She currently serves on the board of Synlogic andis a current and past board member of multiple non-profit organizations.
  • "I am delighted to join the Eiger board at this exciting time in its evolution to a commercial stage biopharmaceutical company," saidMs.

Nitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson

Retrieved on: 
Thursday, November 12, 2020
Companies, Pharmaceutical companies, Industries, Nitrome, AbbVie, Abbott Laboratories

Industry drug discovery and development veteran, James Summers, Ph.D., has been appointed chairperson of the SAB.

Key Points: 
  • Industry drug discovery and development veteran, James Summers, Ph.D., has been appointed chairperson of the SAB.
  • We look forward to Jims leadership and guidance as our SAB chair as we translate Nitrome science into important therapeutics.
  • Under his leadership at Abbott Laboratories and at AbbVie, teams have advanced more than 20 compounds into clinical development.
  • Nitrome has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J.

Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases

Retrieved on: 
Wednesday, April 22, 2020
Other Health, Finance, Stem cells, Pharmaceutical, Managed care, Professional services, General Health, Medical devices, Hospitals, Genetics, Clinical trials, Science, Biotechnology, Health, Research, Companies, Health, AbbVie Inc., Nitrome, Parkinson's disease, Medicine

Nitrome has been widely recognized, and has won multiple awards including the prestigious Target Advancement grant from The Michael J.

Key Points: 
  • Nitrome has been widely recognized, and has won multiple awards including the prestigious Target Advancement grant from The Michael J.
  • Nitrome was also awarded the 2018 AbbVie Golden Ticket, and allocated lab space at the San Francisco incubator MBC BioLabs.
  • Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinsons disease.
  • The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinsons.